Comparative Pharmacology
Head-to-head clinical analysis: ALKERGOT versus D H E 45.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALKERGOT versus D H E 45.
ALKERGOT vs D.H.E. 45
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergotamine tartrate acts as a partial agonist at serotonin (5-HT) receptors, particularly 5-HT1B/1D, and also blocks alpha-adrenergic receptors. It causes vasoconstriction of intracranial blood vessels and reduces extravasation of plasma proteins, thereby alleviating migraine pain. Caffeine enhances ergotamine absorption and may provide additional vasoconstrictive effects.
Dihydroergotamine (DHE) is a semi-synthetic ergot alkaloid that acts as an agonist at serotonin (5-HT1B/1D) receptors, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks. It also has high affinity for alpha-adrenergic receptors and moderate affinity for dopamine D2 receptors.
Oral: Ergotamine 1mg/caffeine 100mg combination: 2 tablets at onset of migraine, then 1 tablet every 30 minutes as needed, maximum 6 tablets per attack, maximum 10 tablets per week.
1 mg intramuscularly or subcutaneously at first sign of headache, repeat hourly up to 3 mg per day, maximum 6 mg per week.
None Documented
None Documented
Terminal elimination half-life is 2–4 hours. Clinical context: Short half-life supports use for acute migraine attacks; frequent dosing may be needed for prolonged symptoms.
2.5 hours (range 2-3.5 hours) for ergotamine; clinical context: short half-life supports its use in acute migraine, but frequent dosing risks ergotism.
Primarily hepatic metabolism followed by biliary and fecal excretion (approx. 90%). Less than 2% is excreted unchanged in urine. Renal elimination of metabolites accounts for about 10%.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 90% of elimination, with 10% fecal.
Category C
Category C
Antimigraine Agent
Antimigraine Agent